Transcriptomics- and 3D imaging-based characterization of the lymphatic vasculature in human skin
Bauer A., Zambounis L., Kritikos I., Lütge A., Sabine A., Heron C.
Animal Study, published in J Exp Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Exp Med (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41186588
- PMCID
- PMC12584878
- DOI
- 10.1084/jem.20242353
- Citations
- 4
Abstract (original English)
Afferent lymphatic vessels (LVs) are present in most vascularized tissues and exert important immune and drainage functions, yet human afferent LVs remain poorly studied. Performing single-cell RNA sequencing of lymphatic endothelial cells (LECs) from human skin and subcutaneous adipose tissue, we identified various LEC subsets, including two valve LEC populations located on the upstream and downstream sides of the valve leaflets. The cell adhesion molecule CD24 emerged as a specific marker of upper valve leaflet LECs in human skin and contributed to lymphatic valve development in murine mesentery. Three-dimensional imaging further revealed several unique features of the human dermal lymphatic network, including a high proportion of LYVE-1+ pre-collecting vessels containing intraluminal valves, virtually no collectors, and absence of lymphatic muscle cell coverage. Moreover, LECs in blind-ended capillaries and around valves in pre-collectors displayed mixed junctional and morphological phenotypes. These findings reveal key differences between human and murine dermal afferent lymphatics and provide a deeper understanding of human lymphatic-related (patho)physiological processes.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.